ទំព័រដើម › Non-Small Cell Lung Cancer › វឺជីនីយ៉ា › Arlington
ការសាកល្បងគ្លីនិកសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុង Arlington, VA
ការសិក្សាចំនួន 104 សម្រាប់ Non-Small Cell Lung Cancer កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ Arlington (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
កំពុងជ្រើសរើសដំណាក់កាល 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · ឆ្ងាយ 5 ម៉ាយ
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists ( Site 0167), Fairfax · ឆ្ងាយ 11 ម៉ាយ
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Virginia Cancer Specialists, PC, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Inova Schar Cancer Institute, Fairfax · ឆ្ងាយ 11 ម៉ាយ
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists ( Site 0114), Fairfax · ឆ្ងាយ 11 ម៉ាយ
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- ALX Center 2, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Site 04, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of PHN-012 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- PHN-012-001 Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists PC, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Inova Schar Cancer Institute Clinical Trials, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
កំពុងជ្រើសរើសដំណាក់កាល 3
- Clinical Study Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, Arlington
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT - Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, PC, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Local Institution - 007-814-D, Arlington
- USOR - Virginia Cancer Specialists - Fairfax Office, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Inova Schar Cancer Institute, Fairfax · ឆ្ងាយ 11 ម៉ាយ
- Next Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists (Fairfax) - USOR, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1/1b Study of IAM1363 in HER2 Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- USO - Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- USO-Virginia Cancer Specialists, PC, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, Fairfax · ឆ្ងាយ 11 ម៉ាយ
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists, PC, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Inova Schar Cancer Institute, Falls Church · ឆ្ងាយ 4 ម៉ាយ
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
កំពុងជ្រើសរើសដំណាក់កាល 3
- Inova Schar Cancer Institute, Fairfax · ឆ្ងាយ 11 ម៉ាយ
- Inova Fair Oaks Hospital, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of DM005 in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Clinical Trial Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- USOR Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Next Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of LY4175408 in Participants With Advanced Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of XB010 in Subjects With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Inova Schar Cancer, Fairfax · ឆ្ងាយ 11 ម៉ាយ
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Texas LLC - Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · ឆ្ងាយ 5 ម៉ាយ
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Next Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · ឆ្ងាយ 5 ម៉ាយ
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · ឆ្ងាយ 5 ម៉ាយ
A 2-part Phase 1/2 Open-label Trial on ODM-212
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
កំពុងជ្រើសរើសដំណាក់កាល 2
- Inova Fairfax Hospital, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT, Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
កំពុងជ្រើសរើសដំណាក់កាល 1
- Dren Investigational Site, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Research Site 102, Fairfax · ឆ្ងាយ 11 ម៉ាយ
- Research Site 112, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Virginia Cancer Specialists, Fairfax · ឆ្ងាយ 11 ម៉ាយ
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Virginia, Fairfax · ឆ្ងាយ 11 ម៉ាយ
ការសាកល្បងសម្រាប់ Non-Small Cell Lung Cancer នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 145
- New York City, NYការសិក្សា 120
- Nashville, TNការសិក្សា 97
- Boston, MAការសិក្សា 90
- Los Angeles, CAការសិក្សា 87
- St. Louis, MOការសិក្សា 73
- Chicago, ILការសិក្សា 61
- Baltimore, MDការសិក្សា 60
- San Antonio, TXការសិក្សា 59
- Columbus, OHការសិក្សា 56
- Washington, DCការសិក្សា 55
- Seattle, WAការសិក្សា 53
ការសិក្សាផ្សេងទៀតនៅក្នុង Arlington
- មហារីកដែលរីករាលដាលការសិក្សា 53
- មហារីកពោះវៀនធំ និងទ្វារមាសការសិក្សា 52
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 48
- មហារីកទ្រូងការសិក្សា 46
- មហារីកស៊ុតការសិក្សា 46
- មហារីកសួតការសិក្សា 41
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 39
- មហារីកតំបក់ការសិក្សា 33
- មហារីកកោសិកាស្រអាប់នៅក្បាល និងបំបៅកការសិក្សា 26
- មហារីកសួតប្រភេទ Small Cellការសិក្សា 23
- មហារីកទ្រូងប្រភេទ Negative បីការសិក្សា 20
- មហារីកក្រពះការសិក្សា 20
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 5 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។